What is Kernicterus (Neonatal Jaundice) Yellowing?
Kernicterus is a rare but serious form of brain injury that occurs when a newborn’s blood contains extremely high levels of bilirubin, the pigment that gives skin and eyes a yellow hue. When bilirubin crosses the blood‑brain barrier, it can deposit in the basal ganglia and other parts of the central nervous system, leading to irreversible neurologic damage. In everyday language, “neonatal jaundice” refers to the more common, usually benign yellowing of a newborn’s skin and sclerae; kernicterus is the extreme end of this spectrum.
Most cases of neonatal jaundice resolve with simple phototherapy or, in rarer cases, a brief blood transfusion. However, if bilirubin levels rise too quickly or are ignored, the risk of kernicterus increases dramatically. Prompt recognition and treatment are therefore essential.
Key points:
- Normal newborn bilirubin levels peak around 2–3 mg/dL in the first 24 hours and usually fall below 12 mg/dL by one week.
- Kernicterus typically develops when total serum bilirubin (TSB) rises above 20–25 mg/dL (depending on gestational age and other risk factors).
- The condition is preventable with early detection and appropriate therapy.
Common Causes
Most causes of severe neonatal jaundice fall into two categories: increased bilirubin production, impaired bilirubin conjugation, or reduced elimination. Below are the most frequent contributors to the level of bilirubin that can lead to kernicterus.
- Physiologic jaundice – normal breakdown of fetal red cells; usually peaks days 2–4 and resolves without treatment.
- Hemolytic disease of the newborn (HDN) – maternal antibodies (e.g., anti‑ Rh, ABO incompatibility) destroy fetal red cells, dramatically increasing bilirubin.
- G6PD deficiency – an inherited enzyme defect that makes red cells susceptible to oxidative stress, leading to rapid hemolysis.
- Hereditary spherocytosis or other red‑cell membrane disorders – cause chronic hemolysis.
- Breast‑feeding jaundice – inadequate milk intake in the first 24–48 hours, leading to dehydration and decreased bilirubin excretion.
- Breast‑milk jaundice – substances in breast milk inhibit bilirubin conjugation, typically presenting after the first week.
- Crigler‑Najjar syndrome type I – a rare genetic lack of the enzyme UDP‑glucuronosyltransferase, preventing bilirubin conjugation.
- Congenital infections (TORCH) – e.g., cytomegalovirus, rubella, or toxoplasmosis, which can damage the liver and impair bilirubin metabolism.
- Prematurity – immature liver enzymes and a larger bilirubin pool increase risk.
- Sepsis or significant illness – causes impaired hepatic function and reduced feeding, both of which raise bilirubin.
Associated Symptoms
While the classic sign of jaundice is yellowing of the skin and the whites of the eyes, kernicterus may be accompanied by neurologic and systemic manifestations.
- Yellow discoloration that starts on the face and spreads down the torso and limbs.
- Dark “coffee‑ground” urine and pale, clay‑colored stools (signs of impaired bilirubin excretion).
- Lethargy or difficulty waking for feeds.
- High‑pitched cry or irritability.
- Poor feeding or failure to thrive.
- Muscle tone abnormalities – floppiness (hypotonia) or, later, stiffness (hypertonia).
- Neurologic signs specific to kernicterus: ataxia, seizures, hearing loss, upward‑gazing eye movements (vertical gaze palsy), and later, cerebral palsy‑like motor deficits.
When to See a Doctor
Newborn jaundice often appears harmless, but certain patterns demand immediate medical attention.
- Yellowing that spreads beyond the face within the first 24 hours of life.
- Any jaundice persisting beyond 14 days in a term infant or beyond 21 days in a preterm infant.
- Dark urine, pale stools, or poor feeding.
- Baby looks unusually sleepy, difficult to arouse, or has a high‑pitched cry.
- Signs of dehydration – sunken fontanelle, dry mucous membranes, or significant weight loss (>10 % of birth weight).
- Any known risk factor (e.g., blood‑type incompatibility, G6PD deficiency, premature birth) and rising jaundice.
When any of these are present, call your pediatrician or go to the nearest emergency department without delay.
Diagnosis
Evaluation of neonatal jaundice and the risk of kernicterus follows a stepwise approach.
Clinical Assessment
- Visual inspection of skin and sclerae for color intensity.
- Age‑specific nomograms (e.g., Bhutani “hour‑specific” charts) to estimate risk based on total serum bilirubin (TSB) level.
- Examination for signs of hemolysis (pallor, hepatosplenomegaly) and infection.
Laboratory Tests
- Serum total bilirubin (TSB) – measured via a heel‑stick or venous draw.
- Direct (conjugated) vs. indirect (unconjugated) bilirubin – kernicterus results from extremely high indirect bilirubin.
- Complete blood count and reticulocyte count – to detect hemolysis.
- Blood type and Coombs test – for alloimmune hemolysis.
- G6PD screening if hemolysis is suspected.
- Liver function panel, blood cultures, and TORCH serologies when infection is a concern.
Imaging & Neuro‑assessment (if kernicterus is suspected)
- Transcranial ultrasound or MRI to evaluate basal ganglia involvement.
- Auditory brain‑stem response (ABR) testing for early hearing loss.
- Neurological exam by a pediatric neurologist.
Treatment Options
The therapeutic goal is to keep bilirubin levels below the neurotoxic threshold while addressing the underlying cause.
Phototherapy
- First‑line treatment for most newborns with TSB ≥ 12–15 mg/dL (depending on age and risk).
- Blue‑green light (≈460 nm) converts bilirubin into water‑soluble isomers that are excreted without conjugation.
- Continuous intensive phototherapy is typically administered in a NICU or specialized intensive‑care nursery.
- Monitor TSB every 4–6 hours; continue until levels fall below treatment threshold.
Exchange Transfusion
- Reserved for TSB > 25 mg/dL or rapid rise despite maximal phototherapy, especially in preterm infants.
- Whole‑blood exchange replaces the infant’s plasma with donor blood, instantly lowering bilirubin and removing circulating antibodies.
- Requires central venous access and close hemodynamic monitoring.
Intravenous Immunoglobulin (IVIG)
- Used in immune‑mediated hemolysis (e.g., ABO or Rh incompatibility) to block antibody‑mediated red‑cell destruction.
- May reduce the need for exchange transfusion when given early.
Addressing Underlying Causes
- Stop breastfeeding temporarily if breast‑milk jaundice is significant; resume after bilirubin declines.
- Hydration and frequent feeds (≈8–12 times/24 h) to enhance bilirubin excretion.
- Treat infections with appropriate antibiotics.
- For G6PD deficiency, avoid oxidative triggers (e.g., certain foods, drugs).
- In rare genetic disorders (e.g., Crigler‑Najjar), liver transplantation may be definitive.
Home Care (after discharge)
- Continue regular feeding schedules – at least 60–90 mL/kg/day of breast milk or formula.
- Observe skin and eye color daily; keep a log of any changes.
- Schedule follow‑up bilirubin check 24–48 hours after any discharge on phototherapy.
- Maintain a safe environment for phototherapy devices at home if prescribed.
Prevention Tips
Many cases of severe jaundice are preventable through early identification and simple measures.
- Prenatal care – maternal blood‑type screening and antibody testing allow anticipatory management of HDN.
- Early newborn assessment – check bilirubin within 24 hours of birth, especially in high‑risk infants (premature, ABO/Rh incompatibility, G6PD).
- Prompt feeding – initiate breastfeeding or formula within the first hour of life; aim for at least 10–12 feedings per day.
- Monitor weight – weight loss > 10 % in the first 5 days warrants evaluation.
- Educate parents about normal jaundice progression and red‑flag signs.
- Vaccination and infection control – prevent sepsis, a major precipitant of hyperbilirubinemia.
- Genetic counseling for families with known enzyme deficiencies (G6PD, Crigler‑Najjar).
Emergency Warning Signs
If any of the following appear, seek emergency care immediately (call 911 or go to the nearest emergency department).
- Rapidly worsening yellowing, especially if it spreads to the chest, abdomen, or limbs.
- New‑onset seizures or twitching.
- Extreme lethargy, inability to wake for feeds, or a “floppy” appearance.
- High‑pitched, inconsolable crying.
- Temperature > 38 °C (100.4 °F) or signs of infection (pustules, umbilical redness).
- Severe dehydration – sunken fontanelle, no tears when crying, dry mouth.
- Persistent vomiting or inability to tolerate any feeds.
Bottom Line
Kernicterus is a preventable neuro‑toxic condition caused by extreme elevations of unconjugated bilirubin in newborns. Recognizing the early signs of jaundice, understanding risk factors, and acting quickly with phototherapy or exchange transfusion can protect a baby’s brain. Parents and caregivers play a crucial role by monitoring skin color, ensuring frequent feeds, and seeking medical help at the first hint of trouble.
References:
- Mayo Clinic. “Neonatal Jaundice.” Link.
- American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” Pediatrics, 2022.
- World Health Organization. “Guidelines on the Management of Neonatal Jaundice.” 2021.
- National Institutes of Health. “Kernicterus.” Link.
- Cleveland Clinic. “Bilirubin and Jaundice in Newborns.” Link.